{"id":"lithium-carbonate-perospirone-hydrochloride","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Polyuria and polydipsia"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Sedation"},{"rate":null,"effect":"Extrapyramidal symptoms"},{"rate":null,"effect":"Thyroid dysfunction"}]},"_chembl":{"chemblId":"CHEMBL1200826","moleculeType":"Small molecule","molecularWeight":"73.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lithium carbonate is a mood stabilizer that inhibits inositol monophosphatase and glycogen synthase kinase-3 (GSK-3), affecting intracellular signaling cascades involved in mood regulation. Perospirone hydrochloride is an atypical antipsychotic that antagonizes dopamine D2 receptors and serotonin 5-HT2A receptors, reducing psychotic symptoms. The combination targets both mood stabilization and antipsychotic effects for treatment of bipolar disorder and related conditions.","oneSentence":"Lithium carbonate modulates intracellular signaling pathways to stabilize mood, while perospirone hydrochloride acts as an atypical antipsychotic by blocking dopamine and serotonin receptors.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:34.382Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bipolar disorder (acute and maintenance treatment)"},{"name":"Schizophrenia with mood symptoms"}]},"trialDetails":[{"nctId":"NCT04826510","phase":"PHASE4","title":"Efficacy and Safety of Peropirone Hydrochloride Tablets in the Treatment of Adolescent Bipolar Disorder Depression","status":"UNKNOWN","sponsor":"Shanghai Mental Health Center","startDate":"2020-11-25","conditions":"Depressive Disorder","enrollment":189}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lithium carbonate + perospirone hydrochloride","genericName":"Lithium carbonate + perospirone hydrochloride","companyName":"Shanghai Mental Health Center","companyId":"shanghai-mental-health-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lithium carbonate modulates intracellular signaling pathways to stabilize mood, while perospirone hydrochloride acts as an atypical antipsychotic by blocking dopamine and serotonin receptors. Used for Bipolar disorder (acute and maintenance treatment), Schizophrenia with mood symptoms.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}